Department of Medical Oncology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA
Raymond Liu, Julia R. Trosman, Elizabeth Shurell Linehan, Nancy P. Gordon, Marti Hennings, Henie James, Thea Abbe, Jed Abraham Katzel, Chun Fai Ng, Megumi Tomita, Jeffrey B. Velotta, Lori C. Sakoda, Kimberly Beringer, Arliene Ravelo, Zheng Zhu, Bruce Rapkin, Christine B. Weldon
Background: Team-based care improves quality, reduces fragmentation and lowers clinician burnout related to ad hoc care coordination. A key teamwork principle is managing timing and sequence of interdependent care (Vogel JOP 2016). The 4R Oncology model featured by the NCI ASCO Teams initiative fosters effective teamwork by facilitating systematic timing / sequence of interdependent care.1 4R is Right Info / Care / Patient / Time. Using a 4R intervention, a large health system created a high-functioning care team and conducted optimizations of guideline-based interdependent care in breast and lung cancers Oct 2020 - Dec 2021.2 We present results of these optimizations. Methods: We compared data from electronic health record on timing and sequence of care between historical control cohorts of patients who received care pre-4R (breast n=274, lung n=173) to the post-optimization 4R cohorts (breast n=211, lung n=140). Patient and tumor characteristics between control and 4R cohorts in both cancers were similar. Results: Timing and sequence of care for 6 of the 7 breast cancer metrics and all 7 lung cancer metrics was significantly improved between the control and 4R cohorts (Table). Despite significant increase, the rate of timely care for some metrics remained low, such as referrals based on distress screening in breast cancer and palliative care consult in lung cancer. Conclusions: The 4R Oncology model is effective in applying teamwork principles and improving timing and sequence of guideline-based care. Opportunities for further care optimizations exist to expand the 4R benefit to a higher number of patients. A learning system established in our institution will inform iterative optimizations. 1. Trosman JOP 2016. 2. Liu JCOOP 2022.
Cancer | Metric | NCCN Guideline | Control Cohort % | 4R cohort % |
---|---|---|---|---|
Breast | Pre-treatment referrals based on distress screening | Breast | 23 | 54* |
Bone density test order for ER+ before endocrine therapy | Breast | 74 | 82* | |
Genetic test results available before surgery | Breast | 57 | 61 | |
ECHO for HER2+ within 6 weeks of 1st appt | Survivorship | 13 | 42* | |
Oncotype result available before medical oncology appt post-surgery | Breast | 40 | 69* | |
Social work contact within 30 days of 1st appt | Distress | 75 | 91* | |
Formal pre-treatment recommendation for alcohol reduction | Breast | 0 | 90* | |
Lung | Palliative care consult for stage IV within 6 weeks of 1st appt | NSCL | 15 | 28* |
Formal screening, referral for falls, frailty, memory, cognition at 1st appt | Older Adult | 0 | 64* | |
Formal screening, referral to dentist at 1st appt | ADA | 0 | 54* | |
Formal screening, referral to flu, other vaccines at 1st appt | Infections | 0 | 44* | |
PET within 2 weeks of diagnosis | NSCL | 54 | 71* | |
PDL1 results within 2.5 weeks of diagnosis for advanced stage | NSCL | 55 | 87* | |
NGS results within 2.5 weeks of obtaining tumor tissue | NSCL | 59 | 80* |
* Statistically significant vs control, p<0.1. 1st appt, 1st appointment after diagnosis. NSCL, Non small cell lung. ADA, American Dental Association.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: George Therapondos
2023 ASCO Quality Care Symposium
First Author: Melanie Lynn Powis
2024 ASCO Quality Care Symposium
First Author: M. Kelsey Kirkwood
2023 ASCO Quality Care Symposium
First Author: Stephen Speicher